High-Sensitivity Troponin T and NT-proBNP Kinetics in Breast Cancer Chemotherapy

Pooja Advani, Jonathan Hoyne, Alvaro Moreno-Aspita, Marcia Dubin, Shelly Brock, Caroline Harlow, Saranya Chumsri, Thomas Suter, Joseph L. Blackshear

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background/Aims: Doxorubicin (DOX) and trastuzumab (TRA) are associated with cardiac dysfunction. Method: High-sensitivity troponin T (hs-TnT) and brain natriuretic peptide attached to the amino acid N-terminal fragment in the prohormone (NT-proBNP) were measured before and on days +1, +2, +3, and +7 during cycles 1 and 2 of therapy with DOX or TRA in breast cancer patients. Results: Five of eleven DOX-treated women, compared with 2/11 TRA-treated women, had undetectable baseline hs-TnT. By day +1 of cycle 2, all the DOX-treated women (p = 0.03) but only 7/11 TRA-treated women (p = ns) had detectible hs-TnT. Time to peak was 1-2 days for both groups. In the DOX-treated women, hs-TnT showed significant peaks from precycle baseline, increases in precycle 1 to precycle 2 levels, and a cycle 1 to cycle 2 peak and area under the curve (AUC). hs-TnT increased from precycle (1, 4.6 ± 6.3 pg/mL) to a cycle 2 peak of 16.1 ± 15.0 pg/mL (p < 0.002). No increases were seen with the TRA treatment. Transient posttreatment increases in NT-proBNP were seen after both therapies. Conclusion: DOX was associated with increased pretreatment baseline, peak, and AUC hs-TnT levels. Both DOX and TRA acutely perturb NT-proBNP. Assessment of pre- and posttreatment hs-TnT could be a means of quantifying cumulative myocardial injury in the course of chemotherapy.

Original languageEnglish (US)
Pages (from-to)334-338
Number of pages5
JournalChemotherapy
DOIs
StateAccepted/In press - Jul 14 2017
Externally publishedYes

Fingerprint

Troponin T
Doxorubicin
Breast Neoplasms
Drug Therapy
Area Under Curve
Brain Natriuretic Peptide
pro-brain natriuretic peptide (1-76)
Trastuzumab
Therapeutics
Amino Acids
Wounds and Injuries

Keywords

  • Brain natriuretic peptide
  • Breast cancer
  • Doxorubicin
  • Echocardiography
  • High-sensitivity troponin T
  • Trastuzumab

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Drug Discovery
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Advani, P., Hoyne, J., Moreno-Aspita, A., Dubin, M., Brock, S., Harlow, C., ... Blackshear, J. L. (Accepted/In press). High-Sensitivity Troponin T and NT-proBNP Kinetics in Breast Cancer Chemotherapy. Chemotherapy, 334-338. https://doi.org/10.1159/000477797

High-Sensitivity Troponin T and NT-proBNP Kinetics in Breast Cancer Chemotherapy. / Advani, Pooja; Hoyne, Jonathan; Moreno-Aspita, Alvaro; Dubin, Marcia; Brock, Shelly; Harlow, Caroline; Chumsri, Saranya; Suter, Thomas; Blackshear, Joseph L.

In: Chemotherapy, 14.07.2017, p. 334-338.

Research output: Contribution to journalArticle

Advani, P, Hoyne, J, Moreno-Aspita, A, Dubin, M, Brock, S, Harlow, C, Chumsri, S, Suter, T & Blackshear, JL 2017, 'High-Sensitivity Troponin T and NT-proBNP Kinetics in Breast Cancer Chemotherapy', Chemotherapy, pp. 334-338. https://doi.org/10.1159/000477797
Advani P, Hoyne J, Moreno-Aspita A, Dubin M, Brock S, Harlow C et al. High-Sensitivity Troponin T and NT-proBNP Kinetics in Breast Cancer Chemotherapy. Chemotherapy. 2017 Jul 14;334-338. https://doi.org/10.1159/000477797
Advani, Pooja ; Hoyne, Jonathan ; Moreno-Aspita, Alvaro ; Dubin, Marcia ; Brock, Shelly ; Harlow, Caroline ; Chumsri, Saranya ; Suter, Thomas ; Blackshear, Joseph L. / High-Sensitivity Troponin T and NT-proBNP Kinetics in Breast Cancer Chemotherapy. In: Chemotherapy. 2017 ; pp. 334-338.
@article{85ef26d41b1048ccb943301ecfff955c,
title = "High-Sensitivity Troponin T and NT-proBNP Kinetics in Breast Cancer Chemotherapy",
abstract = "Background/Aims: Doxorubicin (DOX) and trastuzumab (TRA) are associated with cardiac dysfunction. Method: High-sensitivity troponin T (hs-TnT) and brain natriuretic peptide attached to the amino acid N-terminal fragment in the prohormone (NT-proBNP) were measured before and on days +1, +2, +3, and +7 during cycles 1 and 2 of therapy with DOX or TRA in breast cancer patients. Results: Five of eleven DOX-treated women, compared with 2/11 TRA-treated women, had undetectable baseline hs-TnT. By day +1 of cycle 2, all the DOX-treated women (p = 0.03) but only 7/11 TRA-treated women (p = ns) had detectible hs-TnT. Time to peak was 1-2 days for both groups. In the DOX-treated women, hs-TnT showed significant peaks from precycle baseline, increases in precycle 1 to precycle 2 levels, and a cycle 1 to cycle 2 peak and area under the curve (AUC). hs-TnT increased from precycle (1, 4.6 ± 6.3 pg/mL) to a cycle 2 peak of 16.1 ± 15.0 pg/mL (p < 0.002). No increases were seen with the TRA treatment. Transient posttreatment increases in NT-proBNP were seen after both therapies. Conclusion: DOX was associated with increased pretreatment baseline, peak, and AUC hs-TnT levels. Both DOX and TRA acutely perturb NT-proBNP. Assessment of pre- and posttreatment hs-TnT could be a means of quantifying cumulative myocardial injury in the course of chemotherapy.",
keywords = "Brain natriuretic peptide, Breast cancer, Doxorubicin, Echocardiography, High-sensitivity troponin T, Trastuzumab",
author = "Pooja Advani and Jonathan Hoyne and Alvaro Moreno-Aspita and Marcia Dubin and Shelly Brock and Caroline Harlow and Saranya Chumsri and Thomas Suter and Blackshear, {Joseph L.}",
year = "2017",
month = "7",
day = "14",
doi = "10.1159/000477797",
language = "English (US)",
pages = "334--338",
journal = "Chemotherapy",
issn = "0009-3157",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - High-Sensitivity Troponin T and NT-proBNP Kinetics in Breast Cancer Chemotherapy

AU - Advani, Pooja

AU - Hoyne, Jonathan

AU - Moreno-Aspita, Alvaro

AU - Dubin, Marcia

AU - Brock, Shelly

AU - Harlow, Caroline

AU - Chumsri, Saranya

AU - Suter, Thomas

AU - Blackshear, Joseph L.

PY - 2017/7/14

Y1 - 2017/7/14

N2 - Background/Aims: Doxorubicin (DOX) and trastuzumab (TRA) are associated with cardiac dysfunction. Method: High-sensitivity troponin T (hs-TnT) and brain natriuretic peptide attached to the amino acid N-terminal fragment in the prohormone (NT-proBNP) were measured before and on days +1, +2, +3, and +7 during cycles 1 and 2 of therapy with DOX or TRA in breast cancer patients. Results: Five of eleven DOX-treated women, compared with 2/11 TRA-treated women, had undetectable baseline hs-TnT. By day +1 of cycle 2, all the DOX-treated women (p = 0.03) but only 7/11 TRA-treated women (p = ns) had detectible hs-TnT. Time to peak was 1-2 days for both groups. In the DOX-treated women, hs-TnT showed significant peaks from precycle baseline, increases in precycle 1 to precycle 2 levels, and a cycle 1 to cycle 2 peak and area under the curve (AUC). hs-TnT increased from precycle (1, 4.6 ± 6.3 pg/mL) to a cycle 2 peak of 16.1 ± 15.0 pg/mL (p < 0.002). No increases were seen with the TRA treatment. Transient posttreatment increases in NT-proBNP were seen after both therapies. Conclusion: DOX was associated with increased pretreatment baseline, peak, and AUC hs-TnT levels. Both DOX and TRA acutely perturb NT-proBNP. Assessment of pre- and posttreatment hs-TnT could be a means of quantifying cumulative myocardial injury in the course of chemotherapy.

AB - Background/Aims: Doxorubicin (DOX) and trastuzumab (TRA) are associated with cardiac dysfunction. Method: High-sensitivity troponin T (hs-TnT) and brain natriuretic peptide attached to the amino acid N-terminal fragment in the prohormone (NT-proBNP) were measured before and on days +1, +2, +3, and +7 during cycles 1 and 2 of therapy with DOX or TRA in breast cancer patients. Results: Five of eleven DOX-treated women, compared with 2/11 TRA-treated women, had undetectable baseline hs-TnT. By day +1 of cycle 2, all the DOX-treated women (p = 0.03) but only 7/11 TRA-treated women (p = ns) had detectible hs-TnT. Time to peak was 1-2 days for both groups. In the DOX-treated women, hs-TnT showed significant peaks from precycle baseline, increases in precycle 1 to precycle 2 levels, and a cycle 1 to cycle 2 peak and area under the curve (AUC). hs-TnT increased from precycle (1, 4.6 ± 6.3 pg/mL) to a cycle 2 peak of 16.1 ± 15.0 pg/mL (p < 0.002). No increases were seen with the TRA treatment. Transient posttreatment increases in NT-proBNP were seen after both therapies. Conclusion: DOX was associated with increased pretreatment baseline, peak, and AUC hs-TnT levels. Both DOX and TRA acutely perturb NT-proBNP. Assessment of pre- and posttreatment hs-TnT could be a means of quantifying cumulative myocardial injury in the course of chemotherapy.

KW - Brain natriuretic peptide

KW - Breast cancer

KW - Doxorubicin

KW - Echocardiography

KW - High-sensitivity troponin T

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=85023738731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85023738731&partnerID=8YFLogxK

U2 - 10.1159/000477797

DO - 10.1159/000477797

M3 - Article

C2 - 28704807

AN - SCOPUS:85023738731

SP - 334

EP - 338

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3157

ER -